Palatin Technologies, Inc.
PTNHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePalatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. The company carries a $15.3M market cap, placing it firmly in the micro-cap category. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy.
Market Cap
$15.3M
Beta
-0.07
P/E (TTM)
78.36
P/E (Fwd)
-3.55
EPS (TTM)
$0.11
EPS (Fwd)
$-2.43
ROE
-297.2%
ROA
-65.3%
Cash
$10.2M
Total Debt
$286,662
Free CF
-$13.7M
52W Change
1.4%
Annual Financials
Cash vs Debt
Where PTN stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, PTN finished 49.74% below its 150-day moving average ($17.61) and 43.77% below its 200-day moving average ($15.74). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PTN overbought or oversold?
At the July 15, 2026 close, PTN's RSI(14) was 36.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $10.2M in cash comfortably exceeding the $287K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$13.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -297.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $1.5M (2022) to $0 (2025), a 100% decline worth watching.
PTN's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing PTN.